These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 37697139)

  • 1. Comprehensive profiling of enhancer RNA in stage II/III colorectal cancer defines two prognostic subtypes with implications for immunotherapy.
    Bu X; Liu S; Zhang Z; Wu J; Pan S; Hu Y
    Clin Transl Oncol; 2024 Apr; 26(4):891-904. PubMed ID: 37697139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive characterization of enhancer RNA in hepatocellular carcinoma reveals three immune subtypes with implications for immunotherapy.
    Bu X; Liu S; Wen D; Kan A; Xu Y; Lin X; Shi M
    Mol Ther Oncolytics; 2022 Sep; 26():226-244. PubMed ID: 35919459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 4. Genome-wide enhancer RNA profiling adds molecular links between genetic variation and human cancers.
    Cai YM; Lu ZQ; Li B; Huang JY; Zhang M; Chen C; Fan LY; Ma QY; He CY; Chen SN; Jiang Y; Li YM; Ning CB; Zhang FW; Wang WZ; Liu YZ; Zhang H; Jin M; Wang XY; Han JX; Xiong Z; Cai M; Huang CQ; Yang XJ; Zhu X; Zhu Y; Miao XP; Zhang SK; Wei YC; Tian JB
    Mil Med Res; 2024 Jun; 11(1):36. PubMed ID: 38863031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of ENO2 as a promising novel marker for the progression of colorectal cancer with microsatellite instability-high.
    Cai J; Yang Y; Zhang L; Fang Y; Zhang Y; Tan M; Zhang J; Tang C; Ren H; Wang L; Xiang G; Xu F; Lan L; Li L; Zheng X
    BMC Cancer; 2024 May; 24(1):573. PubMed ID: 38724951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
    Lin A; Zhang J; Luo P
    Front Immunol; 2020; 11():2039. PubMed ID: 32903444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
    Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
    Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
    Marginean EC; Melosky B
    Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subtyping of microsatellite instability-high colorectal cancer.
    Hu W; Yang Y; Qi L; Chen J; Ge W; Zheng S
    Cell Commun Signal; 2019 Jul; 17(1):79. PubMed ID: 31331345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of enhancer RNA identify prognosis-related molecular subtypes in gastric cancer.
    Yan A; Chen Y; Bian R; Wang C; Que H; Shen Y; Lu X
    Cancer Med; 2023 Jan; 12(2):2046-2057. PubMed ID: 35801342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy.
    Sibilio P; Belardinilli F; Licursi V; Paci P; Giannini G
    Biol Direct; 2022 May; 17(1):10. PubMed ID: 35534873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LINC02257, an Enhancer RNA of Prognostic Value in Colon Adenocarcinoma, Correlates With Multi-Omics Immunotherapy-Related Analysis in 33 Cancers.
    Xiao J; Liu Y; Yi J; Liu X
    Front Mol Biosci; 2021; 8():646786. PubMed ID: 33996902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer.
    Huang A; Sun Z; Hong H; Yang Y; Chen J; Gao Z; Gu J
    J Transl Med; 2024 Jun; 22(1):587. PubMed ID: 38902737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-1/PD-L1 inhibitors for early and middle stage microsatellite high-instability and stable colorectal cancer: a review.
    Wu H; Deng M; Xue D; Guo R; Zhang C; Gao J; Li H
    Int J Colorectal Dis; 2024 May; 39(1):83. PubMed ID: 38809459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
    Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
    BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in immunotyping of colorectal cancer.
    Wu Y; Zhuang J; Qu Z; Yang X; Han S
    Front Immunol; 2023; 14():1259461. PubMed ID: 37876934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptomic Profiling Reveals an Enhancer RNA Signature for Recurrence Prediction in Colorectal Cancer.
    Sahu D; Lin CC; Goel A
    Genes (Basel); 2023 Jan; 14(1):. PubMed ID: 36672877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.